Overview

Lycia Therapeutics uses its LYTAC platform to degrade extracellular and membrane proteins, aiming to treat autoimmune and inflammatory diseases and cancer. LYTACs are two-part molecules: one end binds the target protein outside the cell and the other end engages a cell-surface receptor to route the complex to the lysosome for degradation. This approach reaches proteins that intracellular degraders cannot touch, such as membrane proteins and circulating targets. The company seeks to bring first-in-class LYTAC degraders into clinical trials and advance collaborations (including with Eli Lilly) to reach milestones and potential royalties.